Industry News
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement
License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research
License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research
FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years